[Treatment of experimental toxoplasmosis in white mice with plaquenil, daraprim and fumagillin].
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000962:Antimalarials / Q000494:pharmacology*; D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D006886:Hydroxychloroquine; D051379:Mice; D011739:Pyrimethamine; D011804:Quinolines / Q000494:pharmacology*; D012717:Sesquiterpenes; D014123:Toxoplasmosis
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D011804:Quinolines; D012717:Sesquiterpenes; D006886:Hydroxychloroquine; C026211:fumagillin; D011739:Pyrimethamine
ANTIBIOTICS/effects; ANTIMALARIALS/effects; QUINOLINES/effects; TOXOPLASMOSIS/experimental
Terapéutica de la toxoplasmosis experimental del raton blanco con hidroxicloroquina (win 1258-2), 5-p-clorofenil-2, 4-diamino-6-etil pirimidina (pirimetamina o daraprim) y fumagilina (fumidil).